CALIDI BIOTHERAPEUTICS INC (CLDI) Stock Analyst Ratings
USA - NYSEARCA:CLDI - US3207034089 - Common Stock
1.54 USD
+0.02 (+1.32%)
1.57 USD
+0.03 (+1.95%)
ChartMill assigns a Buy % Consensus number of 86% to CLDI. The Buy consensus is the weighted average rating of the current analysts ratings.
CLDI was analyzed by 7 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about CLDI.
In the previous month the buy percentage consensus was at a similar level.
CLDI was analyzed by 7 analysts. More opinions would make the average more meaningful.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-06-27 | Ladenburg Thalmann | Initiate | Buy |
| 2024-05-15 | Baird | Maintains | Outperform -> Outperform |
| 2024-03-21 | Baird | Maintains | Outperform -> Outperform |
| 2024-03-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-22 | HC Wainwright & Co. | Initiate | Buy |
| 2023-10-09 | Baird | Initiate | Outperform |
CALIDI BIOTHERAPEUTICS INC / CLDI FAQ
What is the consensus rating for CALIDI BIOTHERAPEUTICS INC (CLDI) stock?
The consensus rating for CALIDI BIOTHERAPEUTICS INC (CLDI) is 85.7143 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover CALIDI BIOTHERAPEUTICS INC (CLDI) stock?
The number of analysts covering CALIDI BIOTHERAPEUTICS INC (CLDI) is 7.